CD4 and neoplasm: For instance, the alkylating agent temozolomide reduced the intratumor Tregs/CD4+ ratios in tumor-bearing mouse models [69], whereas gemcitabine limited Tregs accumulation in mice affected by pancreatic adenocarcinoma [70].